Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.
Michael Rothrock, MBA, MHA: The potential consequences of recurrent or poorly controlled MDD [major depressive disorder] are going to drive potential additional health care resource utilization. That could be cognitive behavioral health, multiple physician visits, or hospitalization rates for those [whose disease is] uncontrolled. There could be development of resistance or lack of adherence because the patient isn’t seeing any benefit, doesn’t feel better, or [can’t] find a reason they need to take the drug. At the end of the day, these consequences are going to lead to poor control and limited improvement in outcomes.
H. Eric Cannon, PharmD, FAMCP: It has been a fascinating journey moving through the coronavirus disease 2019 pandemic. A number of people who were poorly treated to begin with suddenly had access issues getting into their physician. They felt like they were OK. However, in our emergency department, we’ve seen suicide rates and attempted suicides increase and a lot of people turn to self-medicating. The number of overdoses and things have increased at a pretty steep rate. Those consequences are severe, but we also overlook the consequences of what happens within a family. When you have a spouse who’s severely depressed, not getting treatment, or has stopped treatment, there are huge impacts in the basic social structure of their life.
Transcript edited for clarity.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More